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Mel GreavesAbstract
Paraphrasing Dobzhansky’s famous dictum, I discuss
how interrogating cancer through the lens of evolution
has transformed our understanding of its development,
causality and treatment resistance. The emerging
picture of cancer captures its extensive diversity
and therapeutic resilience, highlighting the need
for more innovative approaches to control.be steady or proceed in jumps—punctuated equilibriumEvolutionary biology and medicine
Dobzhansky’s insight applies not just to biology but to
much in medicine. For example, our vulnerability to
many chronic diseases in modern societies probably
owes much to a mismatch between contemporary life-
styles and historical, evolutionary adaptations [1, 2]. An-
other potent example is with the development of drug
resistance in microbes and parasites which is contingent
upon clonal, evolutionary selection [3]. Similarly, the
emergence of new or more virulent microbial pathogens
reflects the outcome of evolutionary arms races between
the immune system’s pathogen recognition repertoire
and the high mutability of viruses, parasites and bacteria
[4]. It’s a travesty that it is still possible to obtain a med-
ical degree whilst in denial, or lacking understanding, of
the essential tenets of evolutionary biology [5]. But, it is
also likely that some evolutionary biologists are unaware
of the medical implications of their field.
Cancer provides a paradigm for the applicability of
evolutionary principles to a medical problem [6]. An ap-
preciation that cancer clones develop, or evolve, in the
context of a complex tissue ecosystem has transformed
our understanding of cancer biology and highlighted the
need for more innovative approaches to therapy that can
thwart evolutionary resilience [7–9]. An evolutionary
logic pervades all major areas of cancer sciences includ-
ing causation, cancer clone development and resistance
to therapies [10] (Fig. 1).Correspondence: mel.greaves@icr.ac.uk
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The natural history of cancer is illustrated in a very simpli-
fied fashion in Fig. 2. The evolutionary trajectory of a
cancer clone, starting from a single mutant cell and pro-
gressing to a malignant and metastatic clone of ~ 1011
cells, can have very variable dynamics, with time frames
ranging from a few months (some aggressive paediatric
tumours) to one or several decades (many adult epithelial
carcinomas). The tempo of cell population dynamics can
[11]. The majority of initiated tumour clones never evolve
to fully fledged malignant clones [12, 13] but for those
that do, the end game is dissemination in the body, or
metastasis, a territorial hijack with onboard therapeutic
resistance. It’s an evolutionary process, not just in terms of
change over time but in the true Darwinian sense of
random genetic variation and natural selection of the
best-adapted or fittest variants. Cancer clone progression
is equivalent to fast track evolution of an asexual species
of unicellular organisms. But it’s fuelled by the recombina-
torial genetic diversity normally acquired via sexual
reproduction.
These ideas first emerged in the 1970s [14]. The
evidence then was based on observations of serial
changes, over time, in gross chromosomal structural
alterations in cells. The current perspective is more
detailed and contextual [7] with cancer cells subject to
whole genome sequencing [15]. Single cell genetic scru-
tiny [16–20] or analysis of small micro-dissected regions
of tumours [21–23] identifies sub-clonal architectures
from which phylogenic relationships can be inferred.
Clonal phylogenies for cancer cells can reveal early or
founder genetic lesions (present in all cells) and time-
ordered sequences of subsequent mutations. In most
cases, sub-clonal architectures are branching rather than
linear [15–18, 21–24], reminiscent of Charles Darwin’s
iconic ‘I think’ drawing in which he imagined how
different species might evolve from a common ancestor
(Fig. 3). Side branches of individual cancers often have
independent mutations in the same genes, reflecting
parallel or convergent evolution and prevailing selective
pressures on all sub-clones. This new, evolutionarye is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1. Nothing in cancer makes sense except in the light of evolution. Images: Charles Darwin (Cambridge University Library), breast cancer cell
(National Cancer Institute [83])
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ics [24] has considerable practical implications for
patient prognosis, monitoring and treatment [8–10].
There are caveats to these analyses. Cancer cell phylo-
genetic constructs are often based on single time point
snapshots and miss the dynamic shifts in sub-clonal
population structure that occur at early pre-clinical time
points, over time with progression of disease and in re-
currence or relapse. The depth of genomic sequencing is
still limited in most cases and, as a consequence, minor
sub-clones are invisible and the extent of diversity
under-estimated [25].
Although some of the sub-clonal architecture in cancer
derives from neutral evolution or drift [26], particularly inFig. 2. Natural history of cancer. Left: Breast cancer cell (National Cancer Instit
in situ carcinoma (angiogenesis). Photo provided by Professor M A Konerding
(dark patches). Image originally published in JNM [84] and reproduced with p
H, Leibovitch I. The detection of bone metastases in patients with high-risk pr
field-of-view SPECT, 18F–fluoride PET, and 18F–fluoride PET/CT. J Nucl Med. 2006
Inc. Most of this evolutionary process is clinically silent or covertearly phases with low cell numbers [27], a prevailing view
is that cancer cell populations undergo positive, or, occa-
sionally, negative, selection via tissue ecosystem pressures
[7, 28]. In this sense, the highly recurrent genetic changes
in gene copy number or single nucleotide variants can be
seen as adaptive, being selected, in a Darwinian sense, as a
consequence of the fitness benefit they provide [10].
Fitness is expressed via so-called ‘hallmark’ phenotypic
features of cancer cells [29], which include enhanced
proliferation, resistance to signals for cell death or senes-
cence, metabolic changes and epigenetic shifts favouring
self-renewal of stem/progenitor cells at the expense of
differentiation. All of which impact, directly or indirectly,
on reproductive fitness. Some cancers exhibit massiveute [83])Middle: Stereoscan image showing neovascularisation around an
. Right: PET scan showing cancer disseminated throughout the body
ermission: Even-Sapir E, Metser U, Mishani E, Gennady Lievshitz G, Lerman
ostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-
;47:287–97. © by the Society of Nuclear Medicine and Molecular Imaging,
Fig. 3. Critical features of cancer clone phylogenetics. Left: Charles Darwin’s iconic ‘I think’ drawing of a phylogenetic tree from his 1837 Notebook (B)
[85]. Right: Example of subclonal phylogeny based on single cell genetics (in leukemia), taken from author’s own research in [17]. Seven subclones
shown (B2–8), each with mutations listed. B1 (7.1%) are normal cells. CDKN2A in green in box: reiterated mutation of same gene is different branches or
subclones. One subclone (B3) is numerically dominant (at 54.9%)
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ered as an adaptive strategy, gambling on rare ‘win-
ners’, as similarly employed by bacteria under potent
metabolic stress [30].The cancer ecosystem
The cancer tissue ecosystem is itself complex and
dynamic and is altered as a consequence of the invasion
of cancerous cells. Understanding the network of
regulatory interactions within the cancer ecosystem,
involving stromal cells, the vasculature, and invasive
inflammatory cells, is in its infancy. Nevertheless, there
is accumulating evidence that features of the cancer
microenvironment, including hypoxia and acidosis,
diversity of inflammatory cell infiltrates, activated stro-
mal cells and patterns of vascularisation, are major
drivers of cancer clone progression, impacting on clinical
outcome [24, 27, 31–35]. Ecosystem variables may also
provide novel opportunities for therapy [36].
These considerations suggest that it might be pos-
sible to define an evolutionary and ecological index of
individual cancers that is predictive of the likelihood
of progression, metastasis and drug resistance and
which could, in the future, guide critical patient man-
agement decisions [37].Not all cancer cells have equivalent proliferative cap-
acity. Many cancers, if not all, have sub-populations of
cells with stem cell-like features or self-renewal capacity,
i.e. they reproduce themselves at the expense of differen-
tiation [38]. The frequency or proportion of these cells
within a cancer cell population varies greatly, as do their
other phenotypic features, which has led to some confu-
sion on their relevance. However, most cancer sub-
clones contain cells with extensive propagating or stem
cell function [24, 39–41]. It is likely that self-renewing,
or stem, cells are the major cellular substrate for the
selective processes that underlie clonal architecture, pro-
gression of disease, metastasis, recurrence and drug
resistance. As such, they provide both the evolutionary
units of selection [42–44] in cancer and the ultimate
targets for therapeutic control or cure [10, 38, 45, 46].
Technical advances in genomics have driven much of
this paradigm shift in our understanding of cancer biology.
On occasion, this has encouraged a rather gene-centric
view of cancer, not altogether dissimilar to Richard
Dawkins’ selfish gene perspective on evolution itself. Can-
cer has, for example, been defined as ‘a disease of the gen-
ome’ [15]. Mutated genomes lie at the heart of the
emergence and malignant progression of cancer but we
should not ignore the critical, contextual role of the eco-
system habitats in which this adaptive process occurs.
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time is demanding with solid tumours, which, unlike the
blood borne leukaemias, often have topographically segre-
gated sub-clones [21–23]. This means that biopsy-based
samples can be highly biased [8]. A solution to this chal-
lenge is, however, provided by serial screening of cancer-
derived DNA fragments in plasma. This allows presumed
unbiased, sensitive, serial monitoring of cancer clone
evolution, virtually in real time. Applications of this tech-
nology are already impacting on patient management, for
example by detecting the early, pre-clinical re-emergence
of disease or drug-resistant sub-clones [47–49].
Evolutionary origins of vulnerability to cancer
There is less appreciation of the relevance of an evolution-
ary perspective to causation in cancer. Cancer epidemiolo-
gists, understandably, focus on proximate mechanisms
that hold the prospect of intervention—for example with
cigarette smoking, UVB exposure or viruses. It is now well
recognised, from genome-wide association studies
(GWAS), that a very large number (~ 100 s) of inherited
gene variants impact on cancer risk. Individual variants
are mostly in non-coding regulatory regions and, individu-
ally, contribute to only a very modest increase in risk,
conferring odds ratios of ~ 1.01–1.1 [50].
What is missing from this genetic epidemiology
description is an appreciation of vulnerability. Why is it
that animals in effectively all phyla can, and do, develop
cancer [51], including Cnidaria (e.g. Hydra) at the base
of the animal phylogenetic tree [52]? Why is it that can-
cer risk for ageing humans is now off the scale at close
to a 50% lifetime risk?
The ubiquity of cancer can plausibly be ascribed to the
intrinsic ‘design’ fallibilities of replicating organisms [53],
including the essential mutability of DNA. Many cancer
relevant genes recognised as tumour suppressors or on-
cogenes appeared at that time that multi-cellularity
emerged around 700 million years ago [54]. The multi-
cellular contract requires compliance of cell behaviour
and proliferative restraint. But as many cells, and espe-
cially stem cells, retain extensive proliferative or regen-
erative capacity, opportunities exist for mutant cheaters.
And, as in other social groupings [55, 56], cheaters will
occasionally succeed in taking these opportunities. Stem
cells, in particular, are an evolutionary liability with re-
spect to mutability, positive selection and cancer [57].
Moreover, they function in an environment, endogenous
or exogenous, replete with genotoxic challenges that can
damage DNA as with, for example, UVB, natural plant
toxins or oxidative metabolism.
But we still require a plausible explanation of why
humans, at least in modern, developed societies, have
such a high lifetime risk of a cancer diagnosis. Some
ascribe this to a consequence of ageing itself. Ascommon, historical causes of death—famine, predation,
infection, cardio-vascular disease—have come under
control, cancer could then be the default health outcome
in ageing individuals who are post-reproductive and may
have reduced capacity for DNA repair and immune sur-
veillance. Could this just be then the legacy of intrinsic
cancer risk leaking through unrestrained? If so, how
come ageing and large elephants and whales have rather
little cancer (Peto’s paradox) [58, 59]? How come the in-
cidence rates of particular cancers vary substantially (2–
400×) between different places and over time, and as
seen in migrant groups [60]? The time/place patterns of
cancer incidence only make sense if lifestyle factors are a
significant component of risk.
One explanation for at least some of the very high risk
of cancer in humans that this author favours is that it re-
flects the impact of chronic exposure to an evolutionary
mismatch [6, 53]: a mismatch between our rapid social
evolution and ‘modern’ lifestyles versus historical, evolu-
tionary adaptations (Fig. 4). An example of this would be
with the risk of skin cancers in white, Caucasian individ-
uals, which is orders of magnitude greater than the risk
of individuals with black or pigmented skin. Historically,
variable levels of skin pigmentation, via melanin content,
have been selected by environmental pressures. Depig-
mented, pale or white skin was an adaptation to cloudy
northern climes with low UVB levels in Europe, improv-
ing survival prospects and reproductive fitness probably
via enhanced vitamin D levels and, possibly, diminution
of the impact of frostbite [61]. Modern lifestyles and for-
eign exile or travel have disrupted this adaptive context.
This is rapid social evolution that outpaces any prospect
of genetic, evolutionary adaptations. Similar arguments
apply to modern reproductive lifestyles (compounded
with diet)—early menarche, delayed first pregnancy and
diminished breastfeeding that escalate risk of breast can-
cer via a mismatch with evolutionary adaptations of
non-seasonal oestrus and protracted breastfeeding [62,
63]. Reduced microbial exposures in infancy may under-
lie the increased risk of childhood acute lymphoblastic
leukaemia in affluent, developed societies as they deprive
the immune system of the ‘educational’ microbial expos-
ure required for its network settings [63].Ways of escape
When cancer is lethal, this is usually because of two
reasons. Firstly, the cancer clones disseminate or
metastasize to ecotopic tissues, compromising essen-
tial functions. And, secondly, at this advanced stage
cancer cells are almost invariably robust and resistant
to therapy. Thwarting the evolutionary resilience of
cancer can then be seen as the major therapeutic
challenge [10, 64–66].
Fig. 4. Evolutionary origins of vulnerability to cancer. See [63] for detailed discussion of this argument
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only makes sense, in an evolutionary context. Several
distinct routes to therapeutic escape are employed and
each has an evolutionary rationale (Table 1). The ‘classic’
route to drug (or immunotherapy) resistance in cancer
is, essentially, via the same mechanisms as seen with
drug resistance in bacteria, malaria or HIV [3, 67, 68];
namely the positive selection (by therapy) of pre-existing
variants that can evade the drug, or immune predation,
via the serendipitous possession of mutations in the
target pathway. We don’t yet have a Luria-Delbrück
fluctuation test for this. Nevertheless, with highly tar-
geted therapy, escapee cells spawning recurrence of
disease have mutations in drug binding sites and can be
backtracked, in some instances, to tissue prior to drug
exposure [69–71]. Given enough cells and a reasonable
mutation rate, this route to escape is inevitable.
If the therapeutic target, e.g. a mutant kinase, is in a
side branch of the cancer clone’s evolutionary tree rather
than truncal, then targeted therapy with a tyrosine kin-
ase inhibitor (TKI) cannot be curative [72]. It’s then
equivalent to pollarding trees or pruning plants—the
plant, or cancer, shrinks in size and then rebounds with
a flourish. Therapies targeted at critical signalling mole-
cules such as kinases are also readily bypassed by signalTable 1 Routes to escape from targeted therapy in cancer
• Genetic variation i. ‘Target’ segregated in sub-clones, not truncal
ii. ‘Target’ mutated and impervious to drugs
• Epigenetic plasticity i. Inhibited target bypassed by signal redundancy
in network
ii. Quiescent/dormant stem cells intrinsically
resistantredundancy [73, 74], a longstanding, networked feature
of eukaryotic cells [75].
As might have been anticipated from an evolutionary
perspective, cancer stem cells can evade therapeutic pre-
dation via other routes. Normal stem cells spend most
of their time reversibly quiescent and out of proliferative
cell cycle, which renders them less liable to mutation
and damage [76]. They are also well equipped with efflux
pumps for noxious, drug-like natural chemicals. Stem
cells are vital to life—and limited in number. It is unsur-
prising that they will have acquired multiple protective
mechanisms; mechanisms that can be readily co-opted
by cancer stem cells under therapeutic assault [77]. It is
now clear that quiescent or dormant cancer stem cells
are intrinsically resistant to drugs and radiotherapy [38].
They can ‘hunker’ down, using a ploy long adopted by
bacteria and other, eukaryotic, unicellular species [78].
Dormant cancer stem cells can re-enter a proliferative
cycle and regenerate a malignant clone after two decades
or more of ‘sleep’ [79].
Collectively, these escape routes equip cancer cells, es-
pecially in advanced disease with high turnover burdens
and high mutation rates (or genetic instability), with
great resilience (Table 1). Like a tardigrade [80], they can
survive almost any insult.
The one real success in targeted therapy, small
molecule tyrosine kinase inhibitors (TKIs) in chronic
myeloid leukaemia (CML) [81], is contingent upon the
target kinase (ABL1) being the founder lesion in every
cell and the clones having minimal genetic diversity.
Resistant mutants with altered ABL1 kinase do occur
(prior to treatment) but many patients achieve sustained
remissions or re-enter remission following a switch to an
alternative TKI [71]. And when patients are effectively
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protracted period of time, but in a dormant state. CML
stem cells that are quiescent, or dormant, appear to have
no dependence on the mutated ABL1 kinase. The CML
clone isn’t then eradicated but kept under control, its
capacity for evolutionary progression blocked.
Outlook: strategies for control
The extent of cellular and genetic diversity in cancer, both
between and within individual patients, is daunting but
has a logic in terms of normal tissue developmental biol-
ogy and evolutionary processes of drift and selection [10,
28]. We now see that the major challenge in cancer con-
trol is how to thwart the evolutionary resilience of the dis-
ease, especially when it is detected relatively late in its
trajectory, as with pancreatic, CNS, lung and ovarian can-
cers. In principle, several strategies are available to us, all
endorsed by the National Cancer Institute in the USA and
Cancer Research UK. First, despite the contentious argu-
ment that many cancers arise via spontaneous mutation
[82], the majority are potentially preventable. For example
by prudent avoidance (e.g. cigarettes, solar UVB), modified
behaviour (e.g. diet/exercise balance) or prophylaxis (e.g.
virally induced cancers such as HPV/cervical cancer). Sec-
ondly most cancers are curable by surgery or radiotherapy
if detected early when localised.
The main challenge of contemporary cancer therapeu-
tics is with advanced or metastatic disease. The third
essential strategy is to design drug combinations, includ-
ing immunotherapy, and schedules that can thwart the
emergence of resistance in established disease [64] by
either eliminating all cancer stem cells, steering them
into more benign fitness peaks or applying anRestraint,
finesse
Catch it earlyStop it before it
gets started
in situ metastases
Fig. 5. Traffic control of cancer cell evolution. Red: Stop it before it
gets started: prophylactic intervention (e.g. HPV vaccines) or
prudent avoidance (e.g. cigarette tar, UBV). Red + amber: Catch
it early: by surveillance of populations or at risk individuals and early
intervention by surgery or radiotherapy. Green: The cancer has already
escaped. Employ therapeutic strategies to finesse or restrain continued
growth and drug resistance. In situ refers to tumours confined to
primary tissue site. Mets metastatic lesions – cancers disseminated to
ectopic tissue sites, e.g. breast to brain, prostate to bone. Adapted
from author’s reference [10]evolutionary break [65]. ‘Taming’ may be a more
achievable objective than elimination for metastatic dis-
ease [64, 65]. Having a better understanding of the can-
cer ecosystem and its selective pressures might
facilitate novel approaches to control that do not solicit
emergence of resistant sub-clones.
There is not, and will not be, a magic bullet or penicil-
lin equivalent for cancer. We need to intervene at all
three time points in cancer’s evolutionary trajectory
(Fig. 5) if we are to erode further its impact on society.
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